Aspira Pathlab

{
  "main_header": {
    "sid": 1002885,
    "name": "Aspira Pathlab",
    "stock_name": "Aspira Pathlab",
    "full_name": "Aspira Pathlab & Diagnostics Ltd",
    "name_url": "stocks-analysis/aspira-pathlab",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "66.87",
    "chg": 4.05,
    "chgp": "6.45%",
    "dir": 1,
    "prev_price": "62.82",
    "mcapval": "65.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540788,
    "symbol": "",
    "ind_name": "Healthcare Services",
    "ind_code": 94,
    "indexname": "",
    "isin": "INE500C01017",
    "curr_date": "Feb 06",
    "curr_time": "",
    "bse_nse_vol": 192,
    "exc_status": "Active",
    "traded_date": "Feb 06, 2026",
    "traded_date_str": "2026 02 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/aspira-pathlab-1002885-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Aspira Pathlab & Diagnostics Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-aspira-pathlab-diagnostics-ltd-fallingrising-3825449",
        "imagepath": "",
        "date": "2026-02-07 00:45:58",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Strong Intraday Performance and Market Outperformance</strong></p>\n<p>The stock opened with a gap up of 6.65%, signalling robust buying interest from the outset of trading on 06-Feb. It reached an intraday high of ₹67, maintaining a narrow trading range of just ₹0.13, which suggests a consolidation phase after the initial surge. This price action indicates confidence among investors, as Aspira Pathlab outperformed its sector by 6.38% on the day, a considerable margin that highlights its relative strength within the healthcare services space.</p>\n<p>Moreover, the stock is trading above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – a technical indicator often interpreted as a bullish signal. This alignment of moving averages suggests sustained upward momentum and a po..."
      },
      {
        "title": "When is the next results date for Aspira Pathlab & Diagnostics Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-aspira-pathlab-diagnostics-ltd-3823255",
        "imagepath": "",
        "date": "2026-02-05 23:18:36",
        "description": "The next results date for Aspira Pathlab & Diagnostics Ltd is scheduled for 10 February 2026...."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Downgraded to Sell Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-diagnostics-downgraded-to-sell-amid-mixed-financial-and-technical-signals-3817396",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/AspiraPathlabDi_mojoScore_3817396.png",
        "date": "2026-02-03 08:21:47",
        "description": "Aspira Pathlab & Diagnostics Ltd has seen its investment rating downgraded from Hold to Sell as of 2 February 2026, primarily driven by a deterioration in technical indicators despite robust financial performance. The company’s Mojo Score fell to 48.0, reflecting a shift in market sentiment and technical trends, even as its fundamentals remain strong with impressive profit growth and attractive valuation metrics."
      },
      {
        "title": "Aspira Pathlab &amp; Diagnostics Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-amp-diagnostics-ltd-is-rated-hold-3810999",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AspiraPathlabDi_mojoScore_3810999.png",
        "date": "2026-01-30 10:11:27",
        "description": "Aspira Pathlab &amp; Diagnostics Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 Dec 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 30 January 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Aspira Pathlab &amp; Diagnostics Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-amp-diagnostics-ltd-is-rated-hold-3794182",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AspiraPathlabDi_mojoScore_3794182.png",
        "date": "2026-01-19 10:10:03",
        "description": "Aspira Pathlab &amp; Diagnostics Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 Dec 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 19 January 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Aspira Pathlab &amp; Diagnostics Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-amp-diagnostics-ltd-is-rated-hold-3784547",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/AspiraPathlabDi_mojoScore_3784547.png",
        "date": "2026-01-07 10:10:08",
        "description": "Aspira Pathlab &amp; Diagnostics Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 07 January 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Aspira Pathlab & Diagnostics Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-diagnostics-ltd-is-rated-hold-3772016",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AspiraPathlabDi_mojoScore_3772016.png",
        "date": "2025-12-27 10:10:04",
        "description": "Aspira Pathlab & Diagnostics Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 December 2025, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Aspira Pathlab & Diagnostics: Analytical Perspective Shifts Amid Financial and Technical Developments",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-diagnostics-upgraded-to-hold-on-improved-technicals-and-strong-financials-3759706",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AspiraPathlabDi_mojoScore_3759706.png",
        "date": "2025-12-16 08:48:05",
        "description": "Aspira Pathlab & Diagnostics has experienced a notable revision in market assessment following a comprehensive review of its quality, valuation, financial trends, and technical indicators. This shift reflects evolving dynamics in the healthcare services sector and the company’s recent performance metrics."
      },
      {
        "title": "Aspira Pathlab & Diagnostics: Analytical Revisions Reflect Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/aspira-pathlab-diagnostics-downgraded-to-sell-amid-mixed-technicals-and-valuation-concerns-3753106",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AspiraPathlabDi_mojoScore_3753106.png",
        "date": "2025-12-09 09:04:05",
        "description": "Aspira Pathlab & Diagnostics has recently undergone a revision in its market evaluation, reflecting a nuanced shift in analytical perspectives across key parameters including quality, valuation, financial trends, and technical indicators. This article examines the factors influencing these changes and their implications for investors in the healthcare services sector."
      }
    ],
    "total": 6129,
    "sid": "1002885",
    "stock_news_url": "https://www.marketsmojo.com/news/aspira-pathlab-diagnostics-1002885"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Directorate",
      "datetime": "06-Feb-2026",
      "details": "Outcome of Postal Ballot",
      "source": "BSE"
    },
    {
      "caption": "Shareholder Meeting / Postal Ballot-Scrutinizers Report",
      "datetime": "06-Feb-2026",
      "details": "Voting Results & Scrutinizer Report of Postal Ballot conducted by remote e-voting process.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Approval Of Unaudited Standalone Financial Results Alongwith Limited Review Report For The Quarter & Nine Months Ended As On December 31 2025.",
      "datetime": "04-Feb-2026",
      "details": "Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2026 inter alia to consider and approve Unaudited Standalone Financial Results alongwith Limited Review Report for quarter & nine months ended as on December 31 2025 and to transact other businesses.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "10 Feb 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Aspira Pathlab & Diagnostics Ltd falling/rising?

2026-02-07 00:45:58

Strong Intraday Performance and Market Outperformance

The stock opened with a gap up of 6.65%, signalling robust buying interest from the outset of trading on 06-Feb. It reached an intraday high of ₹67, maintaining a narrow trading range of just ₹0.13, which suggests a consolidation phase after the initial surge. This price action indicates confidence among investors, as Aspira Pathlab outperformed its sector by 6.38% on the day, a considerable margin that highlights its relative strength within the healthcare services space.

Moreover, the stock is trading above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – a technical indicator often interpreted as a bullish signal. This alignment of moving averages suggests sustained upward momentum and a po...

Read full news article

When is the next results date for Aspira Pathlab & Diagnostics Ltd?

2026-02-05 23:18:36

The next results date for Aspira Pathlab & Diagnostics Ltd is scheduled for 10 February 2026....

Read full news article

Aspira Pathlab & Diagnostics Downgraded to Sell Amid Mixed Financial and Technical Signals

2026-02-03 08:21:47

Aspira Pathlab & Diagnostics Ltd has seen its investment rating downgraded from Hold to Sell as of 2 February 2026, primarily driven by a deterioration in technical indicators despite robust financial performance. The company’s Mojo Score fell to 48.0, reflecting a shift in market sentiment and technical trends, even as its fundamentals remain strong with impressive profit growth and attractive valuation metrics.

Read full news article

Aspira Pathlab & Diagnostics Ltd is Rated Hold

2026-01-30 10:11:27

Aspira Pathlab & Diagnostics Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 Dec 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 30 January 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Aspira Pathlab & Diagnostics Ltd is Rated Hold

2026-01-19 10:10:03

Aspira Pathlab & Diagnostics Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 Dec 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 19 January 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Aspira Pathlab & Diagnostics Ltd is Rated Hold

2026-01-07 10:10:08

Aspira Pathlab & Diagnostics Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 07 January 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Aspira Pathlab & Diagnostics Ltd is Rated Hold

2025-12-27 10:10:04

Aspira Pathlab & Diagnostics Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 15 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 December 2025, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Aspira Pathlab & Diagnostics: Analytical Perspective Shifts Amid Financial and Technical Developments

2025-12-16 08:48:05

Aspira Pathlab & Diagnostics has experienced a notable revision in market assessment following a comprehensive review of its quality, valuation, financial trends, and technical indicators. This shift reflects evolving dynamics in the healthcare services sector and the company’s recent performance metrics.

Read full news article

Aspira Pathlab & Diagnostics: Analytical Revisions Reflect Mixed Market Signals

2025-12-09 09:04:05

Aspira Pathlab & Diagnostics has recently undergone a revision in its market evaluation, reflecting a nuanced shift in analytical perspectives across key parameters including quality, valuation, financial trends, and technical indicators. This article examines the factors influencing these changes and their implications for investors in the healthcare services sector.

Read full news article

View All News